Given these proprietary CryptigenTM TSAs are uniquely expressed and presented by cancer cells and are broadly shared across patients with the same tumor, they provide a tumor-specific targeted rationale for the development of RNA-based immunotherapies that are shared across broad patient populations.

CryptigenTM TSAs are hidden antigens that have largely escaped detection, but their potential impact and significance have been brought to light through the discovery research of Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer of UdeM.

We use our CryptoMapTM discovery platform to ‘reveal’ these hidden CryptigenTM TSAs, based on an empirically-anchored platform that leverages spatial immunopeptidomics, genomics, and systems bioinformatics.

Typically, our CryptoMapTM technology identifies around 100 aberrantly expressed tumor specific antigens per tumor type, which, when compared to current approaches, has the potential to provide more antigens. This allows us to prioritize aeTSAs on the basis of optimal expression and effective recognition by the immune system, which we believe is critical for recognition and destruction of cold tumors.